LENVIMA (lenvatinib), protein kinase inhibitor

TRANSPARENCY COMMITTEE OPINION

Opinions on drugs - Posted on Jan 29 2016

Inclusion

LENVIMA has Marketing Authorisation in the treatment of progressive, locally advanced or metastatic, differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma refractory to radioactive iodine.
Because of their concurrent development, no direct comparative study versus NEXAVAR (sorafenib) is available.
Given the increase in progression-free survival but lack of demonstrated impact on overall survival and the safety profile, the selection of patients in whom systemic treatment with LENVIMA is justified must be based on various criteria, including the maximum size of metastases (1-2 cm), the symptoms associated with the disease and the rate of progression.

Substantial

minor

Therapeutic use

Évaluation des médicaments

All our publications

My account